CASTOR OIL Explanation Castor oil is obtained from the seeds of the castor bean plant (Ricinus communis L., Euphorbiaceae). The oil consists of a triglyceride of fatty acids. The fatty acid content of castor oil consists of about 88-90% ricinoleic acid, 4-5% linoleic acid, 2-3% oleic acid, 1% palmitic acid, 1% stearic acid, about 1% dihydroxystearic acid, and trace amounts of other fatty acids (Binder et al. 1962). BIOLOGICAL DATA BIOCHEMICAL ASPECTS About 7% of the ricinoleic acid present in a 1 ml oral dose of castor oil given by stomach tube to fasted Sprague-Dawley rats was absorbed into the chyle within a 24-hour period. About 24% of the ricinoleic acid was absorbed if the substance was given to fed rats. Seven weanling rats were given a diet containing 20% castor oil, the animals gained weight on the diet, although at a lower rate than animals fed an olive oil supplemented diet. After eight weeks on the castor oil diet, the amount of ricinoleic acid in the animals' fat pads was about 9.7%. When animals were fed the castor oil diet for four weeks then switched to an olive oil diet for 14 days, the amount of ricinoleic acid in the fat pads decreased to about 2% (Watson & Gordon, 1962). Studies in humans indicated that the percentage absorption of castor oil is inversely proportional to the dose given. A dose of 4 g of castor oil was almost completely absorbed; whereas, 64% of a dose of 50 g appeared in the faeces within 24 hours, and almost 90% of 60 g dose was excreted in the faeces. Doses of 10 g or more of castor oil produced either mild laxation of purgation (Watson et al., 1963). TOXICOLOGICAL STUDIES Special studies on cytotoxicity Ricinoleic acid was cytotoxic in vitro to isolated intestinal epithelial cells from hamsters as based on release of radiolabelled chromium, inhibition of 3-O-methylglucose transport and failure to exclude trypan blue. The cytotoxicity began to occur at ricinoleic acid concentrations greater than about 0.1 mM (Caginella et al., 1977). Special studies on intestinal histology No microscopic changes were noted in the villus architecture of the small intestine of random bred white mice following daily oral dosing with 0.3 ml per day of castor oil for 12 weeks (Gibbins & John, 1970). Substantial architectural changes were seen upon light or electron microscopic examination of the mucosal cells of hamster small intestine perfused in vivo in the presence of 8 mM sodium ricinoleate. After treatment, the villus tips were capped with vaccuolated epithelial cells with disintegrating brush borders; the tight junctions were, however, not altered. Ricinoleate treatment was accompanied by increased mucosal cell exfoliation as evidenced by appearance of DNA in the perfusate. Membrane damage was accompanied by increased sucrase activity and appearance of phospholipid in cell-free aliquots of luminal fluid. There was also an increased clearance of inulin and a 16 000 molecular weight dextran (Cline et al., 1976). Dose-related epithelial damage and increased mucosal permeability was seen upon perfusion of rabbit colon in vivo with 0, 2.5, 5.0, 7.5 and 10.0 mM concentrations of ricinoleate. Only occasional focal epithelial damage was seen with 2.5 mM ricinoleate. Severe damage was seen at 7.5 and 10.0 mM ricinoleate. There were also large dose- related increases in the plasma to lumen clearances of urea and creatinine (Gaginella et al., 1976). Special studies on the incorporation of ricinoleic acid into phospholipids Adult rats were fed for 25-40 days on a diet containing 48% castor oil. Judging from the absence of hydroxy fatty acids, none of the ricinoleic acid from the castor oil was incorporated into the phospholipids of the liver, skeletal muscle, and small intestine. The animals did not eat during the first few days of the experiment and weight loss occurred. Aversion to the diet was soon overcome and in most cases the initial body weight was restored. At no time during the experiment was there any evidence of cartharsis (Steward & Sinclair, 1945). Special studies on gastrointestinal motility and water absorption Sodium ricinoleate at 2 mM concentration caused a 48% reduction in net water absorption in vitro by isolated segments of hamster jejunum. The substance also caused a significant decrease in sodium and chloride absorption, but not potassium absorption (Stewart et al., 1975a). In vivo studies carried out with dogs indicated that 45 ml of castor oil given by stomach tube decreased the activity of circular smooth muscle in the intestine (Stewart et al., 1975a). Ricinoleic acid depressed the spontaneous or induced contractile activity of smooth muscle preparations from rat colon, rabbit jejunum and guinea-pig taenia coli and ileum (Stewart et al. 1975b). Studies with perfused human subjects showed that ricinoleic acid caused a decrease in water absorption by the ileum at intraluminal concentrations of 0.5 mM or higher. Concentrations of about 2 mM or higher caused net secretion of water in the jejunum. Ricinoleic acid was absorbed at about half the rate of oleic acid by the perfused subjects (Ammon et al. 1974). Acute toxicity No data available. Short-term studies No data available. Long-term studies No data available. Comments At low doses castor oil is readily absorbed by man. As the oral dose increases, per cent. absorption decreases and laxation occurs. Castor oil has a long history of use as a laxative and aside from these effects it has been used apparently without harm. At laxation levels castor oil might be expected to inhibit the absorption of fat soluble nutrients, notably vitamins A and D. Therefore, food additive use of castor oil should be kept well below levels where absorption would be inhibited. At doses of 4 g in adults absorption appears to be complete and may be considered as a no-effect level. However in light of the lack of adequate long-term studies of immediate relevance the Committee applied a more conservative margin of safety. EVALUATION Level causing no toxicological effect Man: 70 mg/kg bw. Estimate of acceptable daily intake for man 0-0.7 mg/kg bw. REFERENCES Ammon, H. V., Thomas, P. J. & Phillips, S. F. (1974) J. Clin. Invest., 53, 374 Binder, R. G. et al. (1962) J. Amer. Oil Chem. Soc., 39, 513 Cline, W. S. et al. (1976) J. Clin. Invest., 58, 380 Gaginella, T. S. et al. (1976) Clin. Res., 24, 534A Gaginella, T. S. et al. (1977) J. Pharmacol. exp. Ther., 201, 259 Gibbins, R. L. & John, T. J. (1971) J. Path., 103, 57 Stewart, J. J. et al. (1975a) J. Pharmacol. exp. Ther., 192, 458 Stewart, J. J., Gaginella, T. S. & Bass, P. (1975b) J. Pharmacol. exp. Ther., 195, 347 Stewart, W. C. & Sinclair, R. G. (1945) Arch. Biochem., 8, 7 Watson, W. C. & Gordon, R. S. (1962) Biochem. Pharmacol., 11, 229 Watson, W. C. et al. (1963) J. Pharm. Pharmacol., 15, 183
See Also: Toxicological Abbreviations Castor oil (ICSC) CASTOR OIL (JECFA Evaluation)